Abstract

Purpose:

Carrier screening programs that identify the presence of known mutations have been effective for reducing the incidence of autosomal recessive conditions in the Ashkenazi Jewish (AJ) population and other populations. Yet, these programs have not realized their full potential. Furthermore, many known autosomal recessive and dominant conditions are not screened for and the molecular basis of other conditions for which screening might be offered is unknown.

Methods:

Through literature review and annotation of full sequenced genomes from healthy individuals, we expanded the list of mutations. Mutations were identified in a sample of 128 fully sequenced AJ genomes that were filtered through clinical databases and curated manually for clinical validity and utility using the American College of Medical Genetics and Genomics scoring (ACMG) system. Other known mutations were identified through literature review.

Results:

A panel of 163 mutations was identified for 76 autosomal recessive, 24 autosomal dominant, and 3 X-linked disorders.

Conclusion:

Screening for a broader range of disorders not only could further reduce the incidence of autosomal recessive disorders but also could offer the benefits of early or presymptomatic diagnosis.

Genet Med 18 5, 522–528.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model. Eur J Pediatr 2000;159(suppl 3):S192–S195.

  2. 2.

    , , , et al. An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals. Genet Med 2013;15:178–186.

  3. 3.

    , , , , , The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007;9:665–674.

  4. 4.

    , , , , Application of population screening principles to genetic screening for adult-onset conditions. Genet Test 2001;5:201–211.

  5. 5.

    , , , Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue. Genet Med 2009;11:629–639.

  6. 6.

    , Principles and Practice of Screening for Disease. 1968. . Accessed 17 March, 2014.

  7. 7.

    , , , et al. Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases. JAMA 2007;298:1281–1290.

  8. 8.

    , , , et al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17:405–424.

  9. 9.

    , , , et al.; NHLBI Exome Sequencing Project. Pathogenic variants for Mendelian and complex traits in exomes of 6,517 European and African Americans: implications for the return of incidental results. Am J Hum Genet 2014;95:183–193.

  10. 10.

    , , , et al. Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. Nat Commun 2014;5:4835.

  11. 11.

    National Center for Biotechnology Information. What Is ClinVar? . Accessed 17 March, 2014.

  12. 12.

    A genetic profile of contemporary Jewish populations. Nat Rev Genet 2001;2:891–898.

  13. 13.

    , The population genetics of the Jewish people. Hum Genet 2013;132:119–127.

  14. 14.

    , FMR-1-Related Disorders. 1998. .

  15. 15.

    , , , et al.; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008;10:139–150.

  16. 16.

    , , , et al. Type I mutation in the F11 gene is a third ancestral mutation which causes factor XI deficiency in Ashkenazi Jews. J Thromb Haemost 2013;11:724–730.

  17. 17.

    , , , et al. Classical galactosemia and mutations at the galactose-1-phosphate uridyl transferase (GALT) gene. Hum Mutat 1999;13:417–430.

  18. 18.

    , , , , , Maple syrup urine disease: identification and carrier-frequency determination of a novel founder mutation in the Ashkenazi Jewish population. Am J Hum Genet 2001;69:863–868.

  19. 19.

    , , , et al. Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I. Hum Mutat 2002;19:80–81. Accessed 17 March, 2014.

  20. 20.

    ; Professional Practice and Guidelines Committee. Carrier screening for spinal muscular atrophy. Genet Med 2008;10:840–842. Accessed 17 March, 2014.

  21. 21.

    , , , et al. Ethnic-specific distribution of mutations in 716 patients with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Mol Genet Metab 2007;90:414–421.

  22. 22.

    , , , , , Parkinson’s disease in patients and obligate carriers of Gaucher disease. Parkinsonism Relat Disord 2013;19:129–131.

  23. 23.

    , , Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Breast Cancer Res 2008;10:208.

  24. 24.

    Nonclassic cystic fibrosis and CFTR-related diseases. Curr Opin Pulm Med 2003;9:498–503.

  25. 25.

    , Unusual presentation of adult Gaucher’s disease: A long and difficult road to diagnosis. Indian J Endocrinol Metab 2011;15:224–226.

  26. 26.

    , , , , , Moderate hearing loss and pseudodominant inheritance due to L90P/35delG mutations in the GJB2 (connexin 26) gene. Genet Couns 2003;14:379–386.

  27. 27.

    , What is the clinical utility of genetic testing? Genet Med 2006;8:448–450.

  28. 28.

    Gaucher disease. Current issues in diagnosis and treatment. NIH Technology Assessment Panel on Gaucher Disease. JAMA 1996;275:548–553.

  29. 29.

    , , , et al. Mutations in the connexin 26 gene (GJB2) among Ashkenazi Jews with nonsyndromic recessive deafness. N Engl J Med 1998;339:1500–1505.

  30. 30.

    GeneDx. Familial Mediterranean Fever. .

  31. 31.

    , , , et al. Familial Mediterranean Fever in the first two years of life: a unique phenotype of disease in evolution. J Pediatr 2010;156:985–989. Accessed 17 March, 2014.

  32. 32.

    , , , , , High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 1985;37:650–667.

  33. 33.

    , , , et al. Molecular screening for diseases frequent in Ashkenazi Jews: lessons learned from more than 100,000 tests performed in a commercial laboratory. Genet Med 2004;6:145–152.

  34. 34.

    , , , et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008;26:5783–5788.

  35. 35.

    Jewish genetic screening grows despite questions about breadth. Nat Med 2011;17:639.

  36. 36.

    , , , et al. Challenges in the clinical application of whole-genome sequencing. Lancet 2010;375:1749–1751.

  37. 37.

    , , , , , What do patients prefer: informed consent models for genetic carrier testing. J Genet Couns 2007;16:539–550.

  38. 38.

    , , Consumers’ desire towards current and prospective reproductive genetic testing. J Genet Couns 2009;18:137–146.

  39. 39.

    The right not to know: an autonomy based approach. J Med Ethics 2004;30:435–9.

Download references

Acknowledgements

We thank Eli Balshan and Michael Groden for assistance with annotation. We acknowledge financial support from the Human Frontier Science Program (S.C.); NIH research grants AG042188 (G.A.); DK62429, DK062422, and DK092235 (J.H.C.); NS050487 and NS060113 (L.N.C.); AG021654 and AG027734 (N.B.); MH089964, MH095458, and MH084098 (T.L.), and CA121852 (computational infrastructure, IPe’er); NSF research grants 08929882 and 0845677 (IPe’er); the Rachel and Louis Rudin Foundation (H.O.); the North Shore–LIJ Health System Foundation (T.L.); the New York Crohn’s Foundation (IPeter); the Parkinson’s Disease Foundation (L.N.C.); the Sharon Levine Corzine Cancer Research Fund (K.O.); and the Andrew Sabin Family Research Fund (K.O.) and whole-exome sequence data from the T2D-GENES Consortium.

Author information

Author notes

    • Brett Baskovich
    • , Susan Hiraki
    •  & Kinnari Upadhyay

    B.B. is the first author. S.H. and K.U. are co-first authors.

Affiliations

  1. Department of Pathology, Montefiore Medical Center, New York, New York, USA

    • Brett Baskovich
    • , Harry Ostrer
    •  & Carole Oddoux
  2. Department of Pathology, Albert Einstein College of Medicine of Yeshiva University, New York, New York, USA

    • Susan Hiraki
    • , Kinnari Upadhyay
    • , Philip Meyer
    • , Nir Barzilai
    • , Gil Atzmon
    • , Harry Ostrer
    •  & Carole Oddoux
  3. The Faculty of Medicine, Braun School of Public Health, Hebrew University of Jerusalem, Jerusalem, Israel

    • Shai Carmi
  4. Department of Genetics, Hebrew University of Jerusalem, Givat Ram, Jerusalem

    • Ariel Darvasi
  5. Department of Genetics, Icahn School of Medicine at Mount Sinai School of Medicine, New York, New York, USA

    • Laurie Ozelius
    • , Inga Peter
    •  & Judy H. Cho
  6. Faculty of Natural Science, University of Haifa, Haifa, Israel

    • Gil Atzmon
  7. Department of Pathology, Columbia University, New York, New York, USA

    • Lorraine Clark
  8. The Feinstein Institute for Medical Research, Manhasset, New York, USA

    • Jin Yu
    •  & Todd Lencz
  9. Department of Computer Science, Columbia University, New York, New York, USA

    • Itsik Pe’er

Authors

  1. Search for Brett Baskovich in:

  2. Search for Susan Hiraki in:

  3. Search for Kinnari Upadhyay in:

  4. Search for Philip Meyer in:

  5. Search for Shai Carmi in:

  6. Search for Nir Barzilai in:

  7. Search for Ariel Darvasi in:

  8. Search for Laurie Ozelius in:

  9. Search for Inga Peter in:

  10. Search for Judy H. Cho in:

  11. Search for Gil Atzmon in:

  12. Search for Lorraine Clark in:

  13. Search for Jin Yu in:

  14. Search for Todd Lencz in:

  15. Search for Itsik Pe’er in:

  16. Search for Harry Ostrer in:

  17. Search for Carole Oddoux in:

Corresponding author

Correspondence to Harry Ostrer.

Supplementary information

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/gim.2015.123

Further reading